BERRUTI, Alfredo

BERRUTI, Alfredo  

Mostra records
Risultati 1 - 20 di 224 (tempo di esecuzione: 0.035 secondi).
Titolo Data di pubblicazione Autore(i) File
A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients 2006 DE FRANCIA S; PIRRO E; ZAPPIA F; DE MARTINO F; SPRIO AE; DAFFARA F; TERZOLO M; BERRUTI A; DI CARLO F; GHEZZO F
A phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbA phase II trial of weekly paclitaxel and gemcitabine in non-small cell lung cancer patients previously treated with platinum and vinorelbine 2004 DONGIOVANNI V ;ADDEO A ;BERRUTI A ;BUFFONI L ;DONGIOVANNI D ;POLIMENI MA ;FISSORE C ;BARONE C ;BERTETTO O
A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. 2012 Apr 1;3(4):819-824. Epub 2012 Jan 16. PubMed Central PMCID: PMC3362404. 2012 Sottile A; Ortega C; Berruti A; Mangioni M; Saponaro S; Polo A; Prati V; Muto G; Aglietta M; Montemurro F.
A prospective study on adjuvant mitotane 2008 F. Daffara; B. Zaggia; A. Ardito; S. De Francia; G. Reimondo; M. Papotti; M. Volante; F. Di Carlo; A. Angeli; A. Berruti; M. Terzolo.
A randomized comparison of high dose epirubicin versus high dose epirubicin plus lonidamine in advanced breast cancer patients. First results from a cooperative group study 1994 Dogliotti L; Berruti A; Buniva T; Zola P; Baù MG; Farris A; Sarobba MG; Bottini A; Alquati P; Deltetto F; Gosso P; Monzeglio C; Moro G; Sussio M; Perroni D.
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 2019 Tucci M.; Roca E.; Ferrari L.; Pia A.; Dalla Volta A.; Bedussi F.; Buttigliero C.; Vittorio Scagliotti G.; Sigala S.; Berruti A.
Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease. 2001 FIORENTINO C; A. BERRUTI; BOTTINI A; BODINI M; BRIZZI MP; BRUNELLI A; MARINI U; ALLEVI G; AGUGGINI S; TIRA A; ALQUATI P; OLIVETTI L; DOGLIOTTI L
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma 2009 Brizzi MP; Sculli CM; Ragni F; Porpiglia F; Tampellini M; Gorzegno G; Priola AM; Dogliotti L; Berruti A.
Acute myeloblastic leukemia associated with mediastinal nonseminomatous germ cell tumors. Report on two cases. 1995 BERRUTI A; PAZE E; FARA E; GORZEGNO G; DOGLIOTTI L
Adjunctive treatment of adrenocortical carcinoma 2008 Terzolo M; Berruti A.
Adjuvant mitotane in adrenocortical carcinoma - Reply 2007 TERZOLO M; FASSNACHT M; BERRUTI A
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. 2019 Calabrese A, Basile V, Puglisi S, Perotti P, Pia A, Saba L, Berchialla P, Porpiglia F, Veltri A, Volante M, Reimondo G, Berruti A, Terzolo M.
Adjuvant mitotane treatment: a prospective experience at the San luigi Hospital, University of Turin, Italy, USA, 2008 2008 F. Daffara; A. Ardito; S. De Francia; G. Reimondo; M. Papotti; M. Volante; F. Di Carlo; A. Angeli; A. Berruti; M. Terzolo
Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study 2021 Kimpel O.; Bedrose S.; Megerle F.; Berruti A.; Terzolo M.; Kroiss M.; Mai K.; Dekkers O.M.; Habra M.A.; Fassnacht M.
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. 2010 Berruti A; Fassnacht M; Baudin E; Hammer G; Haak H; Leboulleux S; Skogseid B; Allolio B; Terzolo M.
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2012 Berruti A; Baudin E; Gelderblom H; Haak HR; Porpiglia F; Fassnacht M; Pentheroudakis G.
Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† 2020 Fassnacht M.; Assie G.; Baudin E.; Eisenhofer G.; de la Fouchardiere C.; Haak H.R.; de Krijger R.; Porpiglia F.; Terzolo M.; Berruti A.
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior. 2010 Papotti M; Volante M; Duregon E; Delsedime L; Terzolo M; Berruti A; Rosai J.
Advances in pancreatic neuroendocrine tumor treatment. 2011 Berruti A; Pia A; Terzolo M.
Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain 2015 Sperlinga, R.; Campagna, S.; Berruti, A.; Laciura, P.; Ginosa, I.; Paoletti, S.; Giuliano, P.L.; Tucci, M.; Rosato, R.; Scagliotti, G.V.; Saini, Andrea